HOME > COMMENTARY
COMMENTARY
-
COMMENTARY/Provisional Deliveries without Agreement on Prices
June 11, 2007
-
COMMENTARY/Show Road Map to the Goal - 30% Share for Generics
June 4, 2007
-
COMMENTARY/Korosho to Consider Introduction of CU System
May 28, 2007
-
Explosion of Shin-Etsu Chemical's Cellulose Production PlantGood Opportunity to Reconsider Raw Material Procurement System
April 30, 2007
-
COMMENTARY/Japan Moves toward Affiliation with PIC/S
April 23, 2007
-
COMMENTARY/India Attracts Increasing Attention of Japanese Pharmas
April 16, 2007
-
COMMENTARY:Growing Market for Biopharmaceuticals
April 2, 2007
-
Japanese Pharma Companies' Licensing Policy: 1 (2) Takeda Pharmaceutical Co., Ltd.
March 26, 2007
-
Comentary
March 26, 2007
-
Japanese Pharma Companies' Licensing Policy: 1 (1) Takeda Pharmaceutical Co., Ltd.
March 26, 2007
-
Future of the Life Sciences Industries: Strategies for Success in 2015
March 19, 2007
-
3 Advantages of Gov't-Private Sector Dialogue Industry Needs to Continuously Present Proposals
February 19, 2007
-
Breakthrough Pipelines of Japanese Pharma Companies Keiji Nakamura, Ph. D. Pharma Forum Institute, Kamakura 248-0026
February 12, 2007
-
Present and Future of Pharmaceutical Companies in Japan -2- -Prospects for 2001 Analyzed Based on Korosho's Vision for the Pharmaceutical Industry-
January 22, 2007
-
Present and Future of Pharmaceutical Companies in Japan -1- -Prospects for 2001 Analyzed Based on Korosho's Vision for the Pharmaceutical Industry-
January 22, 2007
-
COMMENTARY 4 articles
December 25, 2006
-
Reform Promotion Council to Propose Reference Price System Again
December 11, 2006
-
COMMENTARY Major GE Houses Working to Increase Business with Wholesalers
November 13, 2006
-
COMMENTARY New Promotion Code to Go into Effect Next January
October 30, 2006
-
70% of People 40 Years or Older Have Pain in Joints, Lower Back: Survey by Stryker
October 23, 2006
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…